Federal authorities have accused two top officials of CANARX, a Canadian prescription drug provider, of running a long-running scheme to illegally import prescription drugs into the United States, according to court records filed Tuesday.

John Thomas Howard, the company's treasurer and a director, was arrested Sunday on smuggling and conspiracy charges, according to the records. The arrest warrant also charges him with introducing misbranded drugs into interstate commerce and illegal drug importation. No plea has been filed.

His brother, Bob Howard, the company's president and a director, is also wanted in the investigation, according to an affidavit from Dustin Dobbs, a special agent with the Food and Drug Administration's Office of Criminal Investigations. Bob Howard has not yet been taken into custody.

The affidavit says the FDA's investigation found "there is probable cause to believe that (CANARX) illegally imported or caused the illegal importation of prescription drugs into the United States …." It does not specify which medications were involved. The criminal complaint covers the period from Feb. 22, 2017, through April 15, 2026.

CANARX, founded in 2002 and based in Windsor, Ontario, describes itself on its website as the first international prescription provider for the U.S. The company said it sources medications from Canada, the United Kingdom, Australia and New Zealand.

The company's general counsel, Joseph Morris, said in a statement to CNBC: "The Howards deny all the charges against them, will defend vigorously, and expect to be vindicated in court."

The FDA has scrutinized the company before. In 2023, the agency seized medication CANARX was shipping that it said was potentially misbranded and counterfeit. In 2019, the agency sent the company a warning letter saying it was operating in a manner that substitutes FDA-approved drugs with unapproved drugs. Morris responded that the company was not misleading patients, but agreed to stop importing drugs that must be administered by a doctor.

Drugmaker Gilead Sciences has a separate civil lawsuit pending against CANARX and other companies, alleging illegal importation of Biktarvy, its HIV medication. A Gilead spokesperson said the company "has taken strong legal action to protect patients and the integrity of the U.S. medicines supply chain." CANARX has not responded to that lawsuit.